Kiniksa Pharmaceuticals Third Quarter 2026 Earnings Conference Call - KINIKSA PHARMACEUTICALS INTERNATIONAL PLC

Explicit Guidance:

• FY 2026 Revenue: Raised guidance to a range of $1.045 billion to $1.050 billion, driven by robust growth of the Arclis franchise.
• FY 2026 R&D Expenses: Provided full-year guidance of $160 million to $170 million, encompassing KPL-387 and KPL-1161 development costs plus significant Q4 pre-commercial manufacturing costs for KPL-387.
• FY 2026 SG&A Expenses: Provided full-year guidance of $270 million to $280 million (corrected from transcript "2020"), supporting continued Arclis commercialization, Q4 promotional activities, and enhanced patient targeting.
• Q3 2026 Performance: Reported Q3 Arclis revenue of $286 million (58% YoY growth) and net income of $47.3 million.
• Cash Position: Ended Q3 2026 with $568.8 million in cash, generating approximately $43 million in net cash during the quarter.
• Tax Rate & Capital Allocation: No specific tax rate guidance provided; management notes a "judicious" and "pragmatic" approach to capital allocation, evaluating external BD opportunities against a "high bar."

Business-Segment Outlook:

• Arclis (ARCUS/Arclis) Commercialization:
  • Penetration: Targeting expansion from current 23% penetration (3Q 2026) within the 14,000 multiple-recurrence patient population to the 26,000 first-recurrence patient cohort.
  • Prescriber Base: Grew prescriber base by 450 in Q3 to reach 5,450 total prescribers by end of Q3; repeat prescriber rate increased to 30%.
  • Market Dynamics: Physicians are shifting treatment paradigms to administer Arclis earlier (post-NSAIDs/colchicine, pre-corticosteroids); 50% of surveyed physicians support this approach (double the prior three-year average).
  • DTC Campaign: "Heart's Home" campaign driving 12-fold increase in website traffic and 55% of viewers motivated to discuss treatment with providers; plan to expand campaign content and outreach.
• KPL-387 (Pipeline):
  • Clinical Timeline: Pivotal Phase 3 enrollment ongoing; data expected in H2 2027.
  • Commercial Launch: Potential product launch targeted for 2028–2029.
  • Product Profile: Targeting a once-monthly subcutaneous dosing; transition to monotherapy study (posology) designed to inform labeling for patients currently on oral or biologic therapies.
  • Market Reception: 75% of patients prefer monthly liquid/auto-injector profile; 92% of HCPs indicated high likelihood to prescribe vs. current options.
• KPL-1161 (Pipeline):
  • Clinical Timeline: Phase 1 trial expected to commence by end of 2026.
  • Product Profile: Quarterly IL-1 alpha/beta inhibitor; potential to unlock chronic/lifelong disease states via once-quarterly dosing.
  • Indication Selection: No specific indications disclosed yet; focus on leveraging long-acting profile for chronic conditions.

Market and Competitive Outlook:

• Demand Trends: Anticipated expansion of the treatment paradigm for recurrent pericarditis; strong payer approval and patient compliance driving adoption.
• Pricing/Positioning: Strategy focuses on value-driven investments to shift patients from corticosteroids to IL-1 inhibition earlier in the line of therapy.
• Share Shifts: Aiming to capture market share from the 26,000 annual first-recurrence patients currently untreated or treated with traditional therapies.
• Competitive Landscape: No direct competitors mentioned; focus is on educating physicians and patients to differentiate Arclis from existing standard-of-care (NSAIDs, colchicine, steroids, anakinra).

Macro / Industry Outlook:

• Regulatory: Cited 2025 American College of Cardiology Concise Clinical Guidance as a catalyst for shifting treatment paradigms earlier in the disease course.
• Industry Dynamics: Emphasis on AI and machine learning for targeted patient identification and healthcare provider data sourcing to improve market penetration efficiency in a rare disease setting.
• Economic/Interest Rates: No specific commentary on macro-economic rates or FX impacts provided.

Strategic Initiatives:

• Commercial Expansion: Launching expanded DTC "Heart's Home" campaign and enhancing field team targeting to reach widely dispersed patient populations.
• AI Integration: Leveraging AI-supported patient identification and DTC content generation to drive efficiency in a rare disease market.
• M&A/BD: Maintaining an open but high-bar evaluation of external BD opportunities to complement organic growth; no specific M&A targets or timelines announced.
• Capacity: Pre-commercial manufacturing costs for KPL-387 anticipated in Q4 2026.

Risks and Headwinds to Outlook:

• Clinical Execution: KPL-387 timeline depends on Phase 3 trial enrollment and dosing speed; potential delays could shift 2027 data readout or 2028–2029 launch.
• Regulatory Uncertainty: KPL-387 label and indication selection remain data-dependent; KPL-1161 indications not yet finalized.
• Commercial Execution: Growth relies on sustained successful execution of targeted DTC and field strategies; potential headwinds if market adoption slows or payer policies change.
• Disclaimer: Management noted forward-looking statements are subject to risks that may cause actual results to differ materially.

Management Tone on the Future:

• Confidence Level: High confidence in FY2026 revenue trajectory and commercial execution, citing "robust" growth and "strong momentum."
• Strategic Outlook: Optimistic regarding the "substantial growth opportunity" in the recurrent pericarditis market and the potential of the IL-1 alpha/beta inhibition franchise.
• Commitment: CEO expressed determination to "not rest" until helping more patients and building a multi-product commercial platform.
• Hedges: Management consistently uses "data-dependent" language regarding KPL-387 transition studies and potential patient profiles, acknowledging that clinical trial outcomes will dictate final product profiles and launch strategies.

Miscellaneous:

• Key Personnel: Sanj K. Patel (CEO), Ross Mote (COO), Mark Ragosa (CFO), John Paolini (CMO).
• Specific Numbers: Q3 revenue $286M; Q3 cash generation $43M; Q3 prescriber growth +450; Total prescribers 5,450; 30% repeat prescriber rate.
• Study Details: KPL-387 "212 study" focuses on 16-week primary endpoint for transition from various existing therapies to KPL-387 monotherapy.